Critics have drawn parallels between current developments and past controversies:
Larry Ellison and Theranos: Ellison’s involvement in the now-discredited Theranos–a company that raised billions for fraudulent blood-testing technology–raises concerns about due diligence and the potential for overhyped, underperforming ventures.
Moderna’s Questionable Trajectory: Before the pandemic, Moderna was criticized for its secretive management practices and lack of successful products. Industry insiders speculated it might become the “next Theranos.” These warnings took on new gravity following the catastrophic outcomes of COVID-19 mRNA vaccines.
Trump’s GAVI Funding: Despite Trump’s withdrawal from the WHO, critics note his simultaneous allocation of billions to GAVI, the vaccine alliance founded by Bill Gates. This contradiction underscores concerns about transparency and potential conflicts of interest this time around, as well.2
